Antimicrobial Resistance (AMR) Economics of Innovation Taking STRIDES: The Value of Diagnostics Against AMR Read more
Chronic Diseases Value, Affordability, and… Understanding the Full Value of Long-Acting Therapies: less is more? Read more
Health Technology Assessment… Value, Affordability, and… An Analysis of NICE’s Optimised Decisions from 2015 to 2024 Read more
Health Technology Assessment… Value, Affordability, and… Broader value and societal… The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region Read more
Cell and Gene Therapies Value, Affordability, and… Budget Impact Analysis Challenges and Solutions for Budget Impact Analysis of Gene Therapies Read more
Drug Development/R&D Economics of Innovation Competition The Importance of Diversity of Supply in Rare Diseases Markets Read more © VK Studio at stock.adobe.com
Back Bulletin December 2024 Human cost of outdated payment models Read more Bulletin December 2024 Adapting HTA systems for future needs Read more Bulletin November 2024 Who gets what? Health economics in action Read more Bulletin November 2024 Advance towards better, fairer, healthier societies Read more